Norovirus Treatment Market Size Projected To Increase From $2.15 Billion To $3.21 Billion During The Forecast Period
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Norovirus Treatment Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The size of the norovirus treatment market has experienced rapid expansion in recent years. It is projected to increase from $1.94 billion in 2025 to $2.15 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.9%. This historical growth has been driven by factors such as limited public understanding of norovirus management, a strong dependence on hospital-based care, inadequate homecare infrastructure, the absence of standardized approaches for managing symptoms, and minimal use of probiotics and zinc supplementation.
The norovirus treatment sector is anticipated to experience rapid expansion over the coming years. By 2030, the market value is projected to reach $3.22 billion, with a compound annual growth rate (CAGR) of 10.6%. This forecasted growth is driven by rising demand for oral rehydration solutions, the expansion of homecare services and telemedicine, a heightened focus on pediatric and elderly populations, the development of targeted supportive care therapies, and increased healthcare spending alongside awareness campaigns. Key trends shaping this period include a greater adoption of oral rehydration therapies, more frequent use of intravenous fluids for severe cases, the growth of homecare and remote treatment alternatives, expanded utilization of anti-diarrheal and symptom management medications, and an emphasis on norovirus care for children and older adults.
Download A Free Sample Report For Comprehensive Market Insights:
Norovirus Treatment Market Opportunity Drivers: What Is Creating New Revenue Potential?
The rising occurrence of infectious diseases is anticipated to drive the expansion of the norovirus treatment market in the coming period. Infectious diseases, including influenza, tuberculosis, HIV/AIDS, malaria, and norovirus, are conditions triggered by bacteria, viruses, fungi, or parasites that are transmitted between individuals. This rise in infectious diseases is fueled by urban overcrowding, which accelerates the transmission of pathogens within densely populated areas. Norovirus treatment mitigates the effects of these diseases by effectively managing symptoms and curbing transmission through adequate hydration, hygiene, and isolation protocols. By way of illustration, the World Health Organization—an intergovernmental body headquartered in Switzerland—reported in March 2025 that approximately 10.8 million people globally, consisting of 6.0 million males, 3.6 million females, and 1.3 million children, contracted tuberculosis in 2023. Consequently, the growing prevalence of infectious diseases is propelling the growth of the norovirus treatment market.
Norovirus Treatment Market Segmentation And Category Breakdown
The norovirus treatment market covered in this report is segmented –
1) By Treatment: Electrolytes, Intravenous Fluids, Antipyretics, Analgesics, Anti-Diarrheal, Other Treatments
2) By Diagnosis: Bacteria Culture Test, Stool Tests, Other Diagnosis
3) By Route Of Administration: Oral, Intravenous
4) By End User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Electrolytes: Oral Rehydration Salts (ORS), Sports Drinks, Pediatric Electrolyte Solutions
2) By Intravenous Fluids: Crystalloids, Colloids, Lactated Ringer’s Solution
3) By Antipyretics: Acetaminophen (Paracetamol), Ibuprofen, Aspirin
4) By Analgesics: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioid Analgesics, Acetaminophen-Based Analgesics
5) By Anti-Diarrheal: Loperamide, Bismuth Subsalicylate, Diphenoxylate-Atropine
6) By Other Treatments: Antiemetics, Probiotics, Zinc Supplements
Norovirus Treatment Market Innovation Trends Driving Future Development
Major industry players in the norovirus treatment sector are actively pursuing innovative advancements, particularly next-generation mRNA vaccines, with the goal of accelerating the creation of targeted immunizations, bolstering protection against severe infections, and lessening the worldwide impact of norovirus-related health issues. These advanced mRNA vaccines represent a new class of immunizations that utilize specially engineered messenger RNA to direct cells in producing distinct proteins, thereby eliciting a precise immune response characterized by enhanced stability, effectiveness, and flexibility in combating diverse infectious diseases. An example of this progress occurred in October 2024, when Moderna Inc., a US-based biotechnology firm, collaborated with the UK Health Security Agency (UKHSA), a UK governmental body, to initiate the globe’s first Phase 3 clinical trial of an mRNA norovirus vaccine (mRNA-1403) in the UK. This trial introduces a vaccine crafted to target the highly transmissible norovirus by prompting the body to generate viral proteins, stimulating a robust immune reaction without employing live virus particles. Distinctive attributes of this launch include the use of stabilized mRNA for prolonged durability, rapid development capacity in adapting to emerging viral strains, and the capacity to trigger both antibody-based and T-cell-mediated immune responses.
Norovirus Treatment Market Competitive Analysis Of Major Industry Participants
Major companies operating in the norovirus treatment market are Abbott Laboratories, Reckitt Benckiser Group plc, Nestlé Health Science, Otsuka Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Lupin Limited, Mylan (Viatris Inc.), Perrigo Company plc, Haleon plc, Church & Dwight Co. Inc., GlaxoSmithKline Consumer Healthcare, Sanofi Consumer Healthcare, Pfizer Consumer Healthcare, Ferring Pharmaceuticals, Fresenius Kabi AG, Baxter International Inc., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd., Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Pfizer Healthcare India Pvt. Ltd., Mead Johnson Nutrition (Reckitt), Danone Nutricia, Amneal Pharmaceuticals Inc., Ajanta Pharma Ltd.
Access The Complete Norovirus Treatment Market Report:
Norovirus Treatment Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the norovirus treatment market in 2025. The regions covered in the norovirus treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
